PAK4 and hepatocellular carcinoma: Similarly, miR-199a-3p-expressing AT-MSC-derived EVs induce sensitivity to doxorubicin via the downregulation of mTOR and p21-activated kinase 4 (PAK4) in hepatocellular carcinoma cells [131,132].